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Abstract
Background  and  objectives: The  status  migrainosus  is  a  complication  of  migraine  characterized
by severe  headache  for  more  than  72  h  that  did  not  respond  to  treatment,  with  risk  of  stroke
and suicide.  Researches  on  treatment  are  directed  to  drugs  that  stimulate  GABA  receptors;
propofol and  isoﬂurane  act  on  sub-GABAa  receptors  and  theoretically  could  be  interesting.  The
ﬁrst has  been  the  subject  of  research  in  severe  migraine.  Opioids  are  employed  in  pain,  and  its
use in  chronic  headache  is  debatable,  but  these  agents  are  employed  in  acute  cases.  The  goal
is to  present  a  case  of  refractory  status  migrainosus  in  that  we  decided  to  break  the  pain  cycle
by general  anesthesia.
Case  report:  Female  patient,  aged  50  years,  with  status  migrainosus,  in  the  last  ﬁve  days  with
visits to  the  emergency  department,  medicated  parenterally  with  various  agents  without  result.
Without comorbidities,  dehydrated,  described  her  pain  as  ‘‘well  over  10’’  in  Visual  Numeric
Scale (VNS).  After  consulting  the  literature,  and  given  the  apparent  severity  of  the  condi-
tion, we  opted  for  a  general  anesthesia:  induction  with  fentanyl,  propofol,  and  vecuronium
and maintenance  with  isoﬂurane  and  propofol  for  two  hours.  Following  the  treatment,  in  the
postanesthetic  recuperation  (PAR),  the  patient  related  her  pain  as  VNS  3,  and  was  released
after ﬁve  hours  with  VNS  2.  Subsequently,  her  preventive  treatment  was  resumed.
Conclusion:  Status  migrainosus  is  a  rare  disabling  complication  and  anesthetics  have  been  the
subject of  research  in  its  treatment;  the  option  for  general  anesthesia  with  agents  that  stimulate
GABA receptors,  propofol  and  isoﬂurane,  in  association  with  fentanyl,  proved  effective  and
should encourage  new  research.
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Tratamento  do  estado  de  mal-enxaquecoso  pela  anestesia  geral:  relato  de  caso
Resumo
Justiﬁcativa  e  objetivos:  O  estado  de  mal-enxaquecoso  é  complicac¸ão  da  migrânea  caracteri-
zada por  cefaleia  severa  por  mais  de  72  horas  não  responsiva  à  terapêutica  com  risco  de  AVC
e suicídio.  Pesquisas  no  tratamento  se  direcionam  às  drogas  que  estimulam  receptores  GABA;
propofol e  isoﬂurano  atuam  nos  sub-receptores  GABAa  e  teoricamente  poderiam  ser  interes-
santes. O  primeiro  já  foi  objeto  de  pesquisas  na  migrânea  severa.  Opioides  são  empregados  em
dor,seu uso  crônico  nas  cefaleias  é  discutível,  mas  são  empregados  nos  casos  agudos.  O  objetivo
é apresentar  caso  de  estado  de  mal-enxaquecoso  refratário  em  que  se  optou  para  quebrar  o
cicloálgico  por  uma  anestesia  geral.
Relato  de  caso: Paciente  do  sexo  feminino  com  50  anos  em  estado  de  mal-enxaquecoso  havia
cinco dias  com  passagens  anteriores  por  servic¸o  de  urgências,  medicada  por  via  parenteral  com
vários agentes  sem  resultado.  Sem  comorbidades,  desidratada,  descrevia  sua  dor  como  ‘‘muito
superior a  10’’  na  ENV.  Após  consulta  à  literatura,  face  à  gravidade  aparente  do  quadro,optou-
se pela  feitura  de  uma  anestesia  geral;  a  induc¸ão  foi  com  fentanil,  propofol,  vecurônio  e
manutenc¸ão com  isoﬂurano  e  propofol  por  duas  horas.  No  ﬁm,  na  RPA,  no  primeiro  contato
classiﬁcou  sua  dor  com  ENV  3,  teve  alta  após  cinco  horas  com  ENV  2.  Ulteriormente  retomou
seu tratamento  preventivo.
Conclusão:  O  mal-enxaquecoso  é  uma  complicac¸ão  rara  incapacitante  e  anestésicos  têm  sido
objeto de  pesquisas  no  tratamento;  a  opc¸ão  por  uma  anestesia  geral  com  agentes  que  estim-
ulam os  receptores  GABA,  propofol  e  isoﬂurano,  aliados  ao  fentanil,  mostrou-se  eﬁcaz  e  deve
incentivar  pesquisas.
©  2013  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
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ntroduction
he  state  migrainosus  is,  according  to  the  International
eadache  Society,  a  severe  complication  of  migraine
haracterized  by  disabling  pain  crises,  lasts  for  longer  than
2  h  and  is  presented  in  a  continuous  manner  without  remis-
ion  and  unresponsive  to  usual  treatments.1 It  is  a  rare
ondition,  but  always  an  emergency  and  a  challenge  to
rimary  care  physicians.  The  risk  of  stroke  and  suicide
ttempts  are  part  of  the  complications  described  in  the
iterature2,3 and  that  should  be  considered.  The  pathophysi-
logy  responsible  for  this  type  of  evolution  is  still  subject  to
uch  controversy4,5 and  due  to  the  common  failure  of  the
sual  treatment  in  such  circumstances,  various  approaches
n  bouts  of  severe  migraine  with  anesthetic  drugs  have  been
ade,  from  local  endovenous  anesthetics6 to  opioids,7,8
nd  also  with  hypnotics  as  propofol.9--11 This  latter  strat-
gy  has  come  to  very  interesting  results,  and  his  alleged
ction  would  be  the  interaction  with  the  central  GABA
eceptors,9 with  an  mechanism  similar  to  other  anesthetic
gents,  including  inhaled  isoﬂurane,9,12,13 not  necessarily  in
he  same  receptor  subtypes.  Therefore,  other  drugs  with
imilar  mechanism  of  action  in  these  receptors  also  have
een  a  target  of  research  for  the  treatment  of  migraine.9
ome  of  the  doses  of  propofol  proposed  in  the  literature10,11
ere  superior  to  those  used  in  general  anesthesia  and,
lthough  intermittent,  conducted  to  loss  of  consciousness
nd  respiratory  depression,  reaching11 a  bispectral  index
BIS)  of  40.  Given  these  assumptions  in  the  literature,  we
eport  a  case  in  which  a  general  anesthetic  was  successful
n  an  attempt  to  abort  a  crisis  of  severe  status  migrainosus
hich  was  present  in  the  last  ﬁve  days,  after  the  failure  of
everal  attempts  with  the  ﬁrst-line  therapy.
a
t
a
wase report
emale  patient,  50  years  old,  1.75  m  tall  and  with  70  kg,
ith  a  history  of  migraine  since  adolescence,  with  bouts  of
ery  variable  frequency,  without  other  comorbidities.  The
atient  has  had  several  irregular  treatments,  and  at  that
ccasion  was  being  preventively  medicated  with  amitripty-
ine  25  mg  at  night  and  atenolol  50  mg  in  the  morning.  During
rises,  the  patient  made  use  of  triptans;  in  her  visit,  we  sus-
ected  of  abuse  of  that  last  medication.  At  that  time,  she
as  in  a  crisis  of  ﬁve  days  duration,  and  unresponsive  to  all
reatment  attempts,  with  several  passages  in  the  emergency
epartment,  with  use  of  intravenous  dipyrone  1  g,  dexa-
ethasone  4  and  8  mg,  chlorpromazine  25  mg,  haloperidol
 mg,  ketoprofen  100  mg,  meperidine  30  mg  and  40  mg,  lido-
aine  100  mg,  sodium  valproate  100  mg,  and  antiemetics,
ome  of  them  more  than  once,  all  without  any  satisfactory
esult;  without  food  for  three  days,  no  vomiting,  but  had
ausea  and  photophobia,  was  dehydrated  and  described  her
ain,  with  difﬁculty,  as  ‘‘far  superior’’  to  10  in  the  Visual
umeric  Scale  (VNS)!  In  consultation  with  a  member  of  the
ain  Clinic  of  the  institution  in  search  of  a  solution,  a  liter-
ture  survey  was  conducted  and  found  the  use  of  propofol
nd  opioids  in  refractory  migraine  and  similarities  of  action
f  the  ﬁrst  drug  with  inhalational  anesthetics.  Given  the
ailure  of  previous  therapies,  the  description  in  the  liter-
ture  of  drugs,  doses  and  procedures  which,  in  the  view
f  an  anesthesiologist,  conﬁgured  an  approach  that  practi-
ally  was  an  anesthesia,  even  with  loss  of  consciousness  and
irway  obstruction,  and  that  were  conducted  in  an  induc-
ion  of  anesthesia  ward  or  anesthesia  recovery  room  with
ll  available  and  habitual  anesthetic  monitoring  present,8,9
e  considered  to  accomplish  a  general  anesthesia  as  a  last
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RTreatment  of  status  migrainosus  by  general  anesthesia  
attempt  to  stop  the  pain  status.  After  careful  explanation
to  the  patient,  and  verifying  her  fasting  status,  we  obtained
her  informed  consent,  proceeding  with  a  clinical  exam:
blood  pressure  was  150  ×  90  mm  Hg,  heart  rate  =  104  bpm,
with  no  other  noteworthy  ﬁndings.  The  patient  was  taken
to  the  operating  room,  with  ECG  monitoring  with  similar
DII,  pulse  oximetry  and  noninvasive  blood  pressure  determi-
nation  and  inducted  with  fentanyl  200  g,  propofol  150  mg
and  vecuronium  7  mg  after  ventilation  by  mask  with  O2
100%.  The  patient  was  intubated  and  underwent  controlled
mechanical  ventilation  keeping  saturation  always  above  98%
and  capnometry  with  values  between  34  and  36  mmHg.
Maintenance  of  anesthesia  was  performed  with  isoﬂurane
0.5%  in  oxygen  40%  and  continuous  infusion  of  propofol
1  mg  kg−1 h  for  two  hours.  The  patient  remained  hemody-
namically  stable  throughout  this  period.  After  that,  the
patient  was  decurarized,  awakened,  extubated  and  taken
to  the  postanesthesia  recovery  room.  Once  the  ﬁrst  contact
was  possible,  the  patient  quantiﬁed  and  described  consid-
erable  improvement  her  headache,  having  rated  her  pain
as  VAS  =  3.  After  ﬁve  hours,  the  patient  was  discharged.
Before  that,  the  patient  drank  water,  remained  without
nausea  and  rated  her  pain  as  VNS  =  2.  A  week  after  her
discharge,  the  patient  reported  that  her  headache  had  stabi-
lized,  with  a  pattern  alike  the  circumstances  preceding  the
status  migrainosus  crisis,  which  allowed  the  reintroduction
of  the  usual  preventive  medication  by  her  attending  doctor.
Discussion
It  is  estimated  that  migraine  has  a  prevalence  of  15%  in
the  general  population14;  of  this  percentage,  1.4--2.2%  is
present  in  the  form  of  chronic  migraine,15 that,  in  adult-
hood,  affects  women  twice,  as  compared  with  men.16
The  treatment  of  migraine  is  targeted  at  relieving  the
symptoms  by  administration  of  analgesics,  nonsteroid  anti-
inﬂammatory  drugs,  ergot  alkaloids,  triptans,  antiemetics
and  opioids.  Preventive  therapy  makes  frequent  use  of  beta-
blockers,  antidepressants  and  antiepileptic  drugs,  but  a
number  of  patients  demonstrate  refractoriness,  and  that  is
a  major  challenge.  During  crises,  the  absorption  of  the  oral
medication  becomes  affected,11 and  the  parenteral  via  is
preferred.  Status  migrainosus  is  a  complication  of  its  evolu-
tion  and,  although  considered  rare,  a  prospective  study17
of  2006  showed  that  at  some  point  of  their  lives  about
20%  of  patients  with  chronic  migraine  experienced  pain  for
longer  than  72  h.  Modiﬁcations  of  neurotransmission  occur
in  migraine  and  studies  have  shown  that  these  patients
have  an  alteration  in  the  metabolism  of  serotonin  (5-HT).
Potent  agonists  of  5-HT  receptors  with  antimigraine  activity
have  their  effects  explained  by  the  reduction  of  vasogenic
inﬂammation  and  partly  by  the  vasoconstrictor  effects  on
meninges,  upon  stimulation  of  5-HT  receptors.11 By  1985
it  was  demonstrated  that  GABA  would  exert  an  inhibitory
control  over  serotonergic  neurons18 and  that  drugs  effec-
tive  in  ﬁghting  migraine  have  their  effects  mediated  by
the  agonism  of  GABAa  receptors,  increase  of  GABA  in  the
brain  and  decrease  in  the  frequency  of  stimulation  of  the
dorsal  raphe  serotonergic  cells.19 Since  1996,  with  the  work
of  Cutrer  and  Moskowitz,20 it  is  known  that  the  prospect  of
new  drugs  for  migraine  treatment  was  in  the  study  of  agents409
ith  high  afﬁnity  for  GABAa  receptor  and  their  modulation
ites.  Given  the  difﬁculty  of  overcome  the  pain  in  severe
onditions,  perhaps  the  ﬁrst  idea  of  using  anesthetics  arose
n  1999  with  the  work  of  Ponnudurai  et  al.,21 who  observed
 protective  effect  of  propofol  (an  hypnotic  agent)  against
ostoperative  headache  in  a  particular  group  of  patients.
ince  then,  several  investigations  with  the  use  of  anesthetic
gents  have  been  conducted.  Propofol  is  a  hypnotic  agent
or  use  in  anesthetic  procedures,  have  antiemetic  properties
nd  its  efﬁcacy  has  been  demonstrated  in  cases  of  severe
igraine.  This  agent  would  act  through  its  agonist  activ-
ty  at  the  GABAa  receptor  subunits  1,  activating  chloride
hannels  and  inhibiting  synaptic  transmission.11 Opioids  are
gents  that  provide  relief  from  pain,  and  are  widely  used  in
nesthesia  and  often  in  great  number  of  painful  conditions.
hen,  their  use  in  refractory  migraine  is  not  surprising.  Their
ontinued  use  is,  however,  a matter  of  controversy.  Some
uthors  found  no  signiﬁcant  improvement  in  the  long  term
n  74%  of  cases,22 while  others  emphasize  their  beneﬁt,7,8
nd  methadone  is  the  most  widely  used  drug  in  these  cir-
umstances.  The  GABAa  subreceptor  is  an  important  target
f  inhalational  anesthetics,12 and  these  drugs,  as  well  as
ntravenous  agents,  stimulate  the  receptor23,24 in  a  mecha-
ism  similar  to  that  of  the  drugs  currently  studied  for  the
reatment  of  migraine,  which  justiﬁes  this  mention  in  the
iterature9 and  the  interest  in  this  case.  General  anesthe-
ia  with  propofol,  fentanyl  and  isoﬂurane  was  an  extreme
ption  in  an  extreme  case  unsolved  for  a  several  days,  and
ts  use  had  its  foundations  with  the  knowledge  of  litera-
ure,  and  should  be  investigated  further  for  more  deﬁnitive
onclusions.  For  this  purpose,  a  protocol  was  subsequently
resented  to  the  Ethics  Research  Committee  and  approval
as  obtained.
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